NRX Pharmaceuticals
NRXP
19 hedge funds and large institutions have $1.29M invested in NRX Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 2 reducing their positions, and 15 closing their positions.
450% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 2
62% more call options, than puts
Call options by funds: $212K | Put options by funds: $131K
4.46% more ownership
Funds ownership: 0.4% → 4.86% (+4.5%)
27% less capital invested
Capital invested by funds: $1.76M → $1.29M (-$475K)
39% less funds holding
Funds holding: 31 → 19 (-12)
73% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$343K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$166K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$84.2K |
| 4 |
VF
Virtu Financial
New York
|
+$60.6K |
| 5 |
NPT
National Philanthropic Trust
Jenkintown,
Pennsylvania
|
+$35.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$89K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$57.9K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$35.4K |
| 4 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
-$29.9K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$20.6K |
NRXP Hedge Fund Activity: Q2 2024 in Review
19 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q2 2024, worth a combined $1.29M — down 27% from $1.76M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of NRXP and 4 opened new positions — a net loss of 11 holders — while 2 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $343K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $89K sold.
- 19 institutional investors held NRX Pharmaceuticals (NRXP) as of Q2 2024, down from 31 in Q1 2024.
- Funds reported $1.29M of NRX Pharmaceuticals stock for Q2 2024, down 27% quarter-over-quarter.
- 4 funds opened new NRX Pharmaceuticals positions in Q2 2024 and 15 closed out, a net change of -11 holders.
- The largest NRX Pharmaceuticals buyer in Q2 2024 was Vanguard Group, an estimated $343K added.
- The largest NRX Pharmaceuticals seller in Q2 2024 was Renaissance Technologies, an estimated $89K sold.
Based on aggregated 13F filings for Q2 2024.